Compare DexCom, Inc. (DXCM) vs Nu Holdings Ltd (NU) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

NU stock trades at $13.96, down 0.25% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with revenue growth from $8.3B in 2024 to $10.6B in 2025 and a net income margin of 26.72%. Recent news highlights expansion in Mexico, including banking approval and 15 million customers, signaling international growth potential. Analyst consensus is a Buy with a $14.98 price target, indicating 7% upside from current levels.

The outlook for NU remains positive due to robust earnings growth and Latin American market expansion, though risks include currency volatility and competitive pressures. With a P/E of 21.41 and ROE of 30.04%, the stock offers value if execution continues. Investors should weigh strong cash flow trends against macroeconomic headwinds in emerging markets.